Primary HPV Screening for Cervical Cancer: Why and How? - SC39

Sunday, May 21, 2023

10:00 AM – 11:00 AM ET

Location: Room 308

CME Credits 1

Sub Topic: Evaluate, Diagnose, and Initiate Management for Reproductive Tract Cancer

Sarah Feldman, MD, MPH (she/her/hers)

Medical Director Ambulatory Gynecologic Oncology
Brigham and Women's Hospital
Harvard Medical School
Boston, MA, United States

Disclosure(s): Uptodate: Honorarium (Ongoing)
Shuk On Annie Leung, MD (she/her/hers)

Physician
McGill University Health Center
McGill University
Montreal West, QC, Canada

Disclosure(s): No financial relationships to disclose
Anne L. Banfield, MD (she/her/hers)

Chair, Ob/Gyn
MedStar St. Mary's Hospital
California, MD, United States

Disclosure(s): No financial relationships to disclose
Debbie Saslow, PhD (she/her/hers)

Strategic Director, Screening & Vaccination
American Cancer Society
Brookhaven, GA, United States

Disclosure(s): No financial relationships to disclose

Session Description
Cervical cancer screening is transitioning from the Pap test to primary human papillomavirus (HPV) testing. Health care professionals are challenged to keep up to date with guidelines and the growing body of literature. This session presented by members of the Provider Workgroup of the American Cancer Society’s Cervical Cancer Screening Initiative will review the why and how of HPV testing.

Disclosure(s):

Sarah Feldman, MD, MPH: Uptodate: Honorarium (Ongoing)

Shuk On Annie Leung, MD: No financial relationships to disclose

Anne L. Banfield, MD: No financial relationships to disclose

Debbie Saslow, PhD: No financial relationships to disclose